Edition:
United States

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

15.05USD
15 Dec 2017
Change (% chg)

$0.21 (+1.42%)
Prev Close
$14.84
Open
$14.87
Day's High
$15.09
Day's Low
$14.76
Volume
347,997
Avg. Vol
156,214
52-wk High
$20.25
52-wk Low
$7.88

Latest Key Developments (Source: Significant Developments)

Akebia Therapeutics reports Q3 loss per share $0.49
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Akebia Therapeutics Inc :Akebia Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.49.Q3 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Akebia Therapeutics Inc -cash, cash equivalents and available for sale securities $329.7 million at sept 30 versus $260.3 million as at dec 31, 2016​.  Full Article

Akebia announces positive top-line results from phase 2 study of vadadustat in Japanese patients
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Akebia Therapeutics Inc :Akebia announces positive top-line results from phase 2 study of vadadustat in Japanese patients with non-dialysis-dependent chronic kidney disease.Says ‍phase 3 study in Japan expected to commence by year-end 2017​.Says co provides Mitsubishi Tanabe with option to access global phase 3 vadadustat data for payments of up to $25 million​.Says ‍results confirm findings from previous studies of vadadustat​.Akebia Therapeutics Inc says MTPC will be responsible for all costs associated with phase 3 vadadustat program in Japan.Akebia Therapeutics Inc says expects to submit a Japanese New Drug Application (JNDA) for vadadustat with an anticipated launch in 2020..  Full Article

Muneer Satter reports 6.48 pct stake in Akebia Therapeutics
Friday, 14 Jul 2017 05:16pm EDT 

July 14 (Reuters) - Akebia Therapeutics Inc :Muneer Satter reports 6.48 percent stake in Akebia Therapeutics Inc as of July 5 - SEC filing.Muneer Satter says acquired common stock of Akebia Therapeutics Inc for investment purposes.  Full Article

Akebia prices public offering of 4 mln shares at $14.50/share
Wednesday, 28 Jun 2017 10:46pm EDT 

June 28 (Reuters) - Akebia Therapeutics Inc ::Akebia announces pricing of public offering of common stock.Pricing of an underwritten public offering of 4 million shares of common stock at a price to public of $14.50 per share.  Full Article

Akebia Therapeutics announces proposed public offering of common stock
Wednesday, 28 Jun 2017 04:15pm EDT 

June 28 (Reuters) - Akebia Therapeutics Inc :Akebia Therapeutics announces proposed public offering of common stock.Akebia Therapeutics Inc - intends to use net proceeds from offering for continued clinical development of vadadustat, among others.  Full Article

Vifor Pharma reports 8.4 pct stake in Akebia Therapeutics
Monday, 22 May 2017 04:20pm EDT 

May 22 (Reuters) - Akebia Therapeutics Inc ::Vifor Pharma Ltd reports a 8.4 percent stake in Akebia Therapeutics Inc as of May 12, 2017 - sec filing.  Full Article

Vifor Pharma and Akebia announce license agreement to provide Vadadustat to Fresenius in U.S.
Tuesday, 16 May 2017 12:58am EDT 

May 16 (Reuters) - Vifor Pharma :Vifor Pharma and Akebia announce exclusive license agreement to provide Vadadustat to Fresenius medical care in the U.S. Upon FDA approval.Will also make a $50 million equity investment in akebia at $14 per share.Vifor pharma -entered into exclusive license agreement to sell vadadustat to fresenius medical care dialysis clinics in united states upon approval by u.s. Fda.Vifor pharma will also make a $50 million equity investment in akebia at $14 per share.Agreement is structured as a profit-sharing arrangement between akebia and vifor pharma.Agreement is structured as a profit-sharing arrangement between akebia and vifor pharma.Vifor pharma - arrangement subject to approval of vadadustat by fda and to inclusion of it in bundled reimbursement model, upon which akebia will receive $20 million payment from vifor.  Full Article

Akebia and Vifor Pharma announce license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval
Monday, 15 May 2017 04:42pm EDT 

May 15 (Reuters) - Akebia Therapeutics Inc :Akebia and Vifor Pharma announce exclusive license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval.Vifor Pharma will also make a $50 million equity investment in akebia at $14 per share.Vifor to exclusively distribute vadadustat to Fresenius Medical Care North America for use solely within dialysis facilities in U.S..  Full Article

Akebia announces Q1 loss per share $1.15
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Akebia Therapeutics Inc :Akebia announces first quarter 2017 financial results.Q1 loss per share $1.15.Q1 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.Akebia Therapeutics Inc says collaboration revenue was $20.9 million for Q1 of 2017.  Full Article

Akebia Therapeutics Q4 loss per share $0.99
Monday, 6 Mar 2017 04:05pm EST 

Akebia Therapeutics Inc : Akebia announces fourth quarter and full-year 2016 financial results . Q4 loss per share $0.99 . Q4 earnings per share view $0.77 -- Thomson Reuters I/B/E/S . Collaboration revenue was $1.5 million for q4 of 2016 .Akebia Therapeutics- collaboration revenue in connection with agreement with Mitsubishi Tanabe Pharma corporation is expected to commence in second half of 2017.  Full Article

BRIEF-Akebia Therapeutics reports Q3 loss per share $0.49

* Akebia Therapeutics announces third quarter 2017 financial results